✦ LIBER ✦

Pentoxifylline vs. corticosteroid to treat severe alcoholic hepatitis: A randomised, non-inferiority, open trial

✍ Scribed by Park, Seung Ha; Kim, Dong Joon; Kim, Young Seok; Yim, Hyung Joon; Tak, Won Young; Lee, Heon Ju; Sohn, Joo Hyun; Yoon, Ki Tae; Kim, In Hee; Kim, Hyoung Su; Um, Soon Ho; Baik, Soon Koo; Lee, June Sung; Suk, Ki Tae; Kim, Sang Gyune; Suh, Sang Jun; Park, Soo Young; Kim, Tae Yeob; Jang, Jae Young

Book ID: 122277582
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 658 KB
Volume: 61
Category: Article
ISSN: 0168-8278
DOI: 10.1016/j.jhep.2014.05.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

536 SHORT-TERM SURVIVAL IN PATIENTS WITH

536 SHORT-TERM SURVIVAL IN PATIENTS WITH SEVERE ALCOHOLIC HEPATITIS TREATED WITH PENTOXIFYLLINE vs. CORTICOSTEROID: A NON-INFERIORITY TRIAL – A PRELIMINARY REPORT

✍ Kim, D.J.; Suk, K.T.; Park, S.H.; Tak, W.Y.; Yim, H.J.; Um, S.H.; Yoon, K.T.; Ki 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB

787 A PROSPECTIVE RANDOMISED TRIAL TO CO

787 A PROSPECTIVE RANDOMISED TRIAL TO COMPARE THE EFFICACY OF CORTICOSTEROIDS PLUS PENTOXIFYLLINE VERSUS CORTICOSTEROIDS ALONE IN THE TREATMENT OF SEVERE ALCOHOLIC HEPATITIS

✍ S.S. Sidhu; O. Goyal; P. Singla; D. Gupta; R.S. Chhina; A. Sood 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 48 KB

Tu1822 Mycophenolate Mofetil (MMF) in St

Tu1822 Mycophenolate Mofetil (MMF) in Steroid Non-Responsive Acute Severe Alcoholic Hepatitis (Asah): A Sequentially Randomised Open Label Prospective Clinical (Mash Trial)

✍ Basu, Patrick; Shah, Niraj J.; Aloysius, Mark; Brown, Robert S. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 270 KB

Insulin degludec, an ultra-longacting ba

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

✍ Simon Heller; John Buse; Miles Fisher; Satish Garg; Michel Marre; Ludwig Merker; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 271 KB

Insulin degludec, an ultra-longacting ba

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

✍ Alan J Garber; Allen B King; Stefano Del Prato; Seamus Sreenan; Mustafa K Balci; 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 284 KB

Efficacy and safety of insulin degludec

Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials

✍ Zinman, Bernard; DeVries, J Hans; Bode, Bruce; Russell-Jones, David; Leiter, Law 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 337 KB